Connecting Families to Overcome Ovarian Cancer
Testing a Low Cost Population- and Theory-Based Outreach Intervention to Engage Ovarian Cancer Survivors and Their Close Relatives to Consider Genetic Services
2 other identifiers
interventional
2,331
1 country
1
Brief Summary
This study tests a multi-component, low cost, message-based communication outreach intervention to engage ovarian cancer survivors and their at-risk relatives in considering cancer genetic services. The intervention includes foot-in-the-door techniques, tailored/targeted print, website support, and short messages to expand reach of prevention messages.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable ovarian-cancer
Started Jul 2021
Shorter than P25 for not_applicable ovarian-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 14, 2021
CompletedFirst Posted
Study publicly available on registry
June 15, 2021
CompletedStudy Start
First participant enrolled
July 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 21, 2023
CompletedResults Posted
Study results publicly available
October 3, 2024
CompletedOctober 3, 2024
September 1, 2024
1.6 years
June 14, 2021
February 20, 2024
September 30, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Number of Survivors Using Website Access Code
Survivor reach is assessed as the number of the eligible survivors identified and contacted by GCR who used their unique login to access the study website.
Up to 19 months
Number of Survivors Consenting to Participate in the Study
Survivor reach is assessed as the number of the eligible survivors identified and contacted by GCR who used their unique login code to access the study website and consented to participate in the study while visiting the website.
Up to 19 months
Number of Survivors Creating a Study Login
Survivor reach is assessed as the number of the eligible survivors identified and contacted by GCR who access the study website, consented to participate in the study, and created their own personal study login on the website.
Up to 19 months
Number of Relatives of Survivors Using the Website Access Code
Close relative reach is assessed as the number of close relatives enumerated by survivors who used their unique login code to access the study website.
Up to 19 months
Number of Relatives of Survivors Consenting to Participate in the Study
Close relative reach is assessed as the number of close relatives enumerated by survivors who accessed the website and consented to participate in the study while they were using the website.
Up to 19 months
Number of Relatives of Survivors Creating a Login
Close relative reach is assessed as the number of close relatives enumerated by survivors who accessed the study website, gave consent to participate in the study, and created their own personal study login on the study website.
Up to 19 months
Secondary Outcomes (11)
Relative Contact Option Selected by Survivors
Up to 19 months
Number of Survivors Requesting Telegenetic Counseling
Up to 19 months
Number of Survivors Completing Telegenetic Counseling
Up to 19 months
Number of Relatives Requesting Telegenetic Counseling
Up to 19 months
Number of Relatives Completing Telegenetic Counseling
Up to 19 months
- +6 more secondary outcomes
Study Arms (4)
Message-based Outreach Intervention (MBI) for Survivors
EXPERIMENTALCancer survivors randomized to receive a targeted letter with a unique website login code, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
Standard Outreach for Survivors
ACTIVE COMPARATORCancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
Message-based Outreach Intervention for Close Relatives
EXPERIMENTALClose relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
Standard Outreach for Close Relatives
ACTIVE COMPARATORClose relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
Interventions
The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
Eligibility Criteria
You may qualify if:
- in the Georgia Cancer Registry (GSR)
- diagnosed with ovarian, fallopian tube, or peritoneal cancers
- lived in Georgia at the time of diagnosis
- not deceased per the registry's records
- have a mailing address in GSR records
- years or older
- able to access the internet
- a 1st or 2nd degree relative of the survivor
- able to read English
- non-incarcerated or institutionalized
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emory Universitylead
- National Cancer Institute (NCI)collaborator
Study Sites (1)
Emory University
Atlanta, Georgia, 30322, United States
Related Publications (2)
Guan Y, McBride CM, Zhao J, Pentz RD, Escoffery C, Liu Y, Cao Y, An W, Shepperd JA, Ward KC. Testing a Population-Based Outreach Intervention for Ovarian Cancer Survivors to Encourage their Close Relatives to Consider Genetic Counseling. Cancer Epidemiol Biomarkers Prev. 2024 Sep 3;33(9):1185-1193. doi: 10.1158/1055-9965.EPI-24-0147.
PMID: 38912902RESULTShepperd JA, McBride CM, An W, Zhao J, Pentz RD, Escoffery C, Ward K, Guan Y. Trust and Privacy Concerns Among Cancer Survivors Who Did Not Visit a Research Website Offering Free Genetic Counseling Services for Families: Survey Study. J Med Internet Res. 2025 May 6;27:e64228. doi: 10.2196/64228.
PMID: 40327861DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Yue Guan, PhD
- Organization
- Emory University
Study Officials
- PRINCIPAL INVESTIGATOR
Colleen McBride, PhD
Emory University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 14, 2021
First Posted
June 15, 2021
Study Start
July 24, 2021
Primary Completion
February 21, 2023
Study Completion
February 21, 2023
Last Updated
October 3, 2024
Results First Posted
October 3, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Data will be available for sharing immediately following the publication and release of the key manuscripts tied to the primary aims of this study, and ending approximately 18 months after funding ends.
- Access Criteria
- Individual participant data will be available for sharing with researchers who provide a methodologically sound proposal, in order to achieve the aims stated in the approved proposal. Proposals should be directed to Dr. Colleen McBride at colleen.marie.mcbride@emory.edu. To gain access, data requestors will need to sign a data access agreement.
All of the individual participant data collected during the trial will be available for sharing, after de-identification.